Want to see ABCL full AI Analyst Report?
ABCL Stock Chart & Stats
$4.01
-$0.28(-8.54%)
At close: 4:00 PM EST
$4.01
-$0.28(-8.54%)
Day’s Range― - ―
52-Week Range$2.75 - $8.44
Previous CloseN/A
Volume1.71M
Average Volume (3M)6.77M
Market Cap
$1.97B
Enterprise Value$668.18
Total Cash (Recent Filing)$504.73M
Total Debt (Recent Filing)$140.18M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding305,375,400
10 Day Avg. Volume6,073,906
30 Day Avg. Volume6,767,783
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.20Price Target Upside154.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$31.99M
Bulls Say, Bears Say
Bulls Say
Liquidity RunwayA roughly $655M liquidity buffer funds multi‑year pipeline investment, lowers immediate dilution risk and gives management time to deliver Phase II/IND catalysts. This financial flexibility supports sustained R&D spending and strategic optioning without urgent financing needs.
Strategic PartnershipsThe Jazz collaboration provides significant non‑dilutive upfront funding, potential milestone and royalty streams, and external validation of the discovery platform. It diversifies near‑term funding sources and structurally extends commercial pathways into oncology and solid tumors.
Board & Governance StrengthRecent independent director additions bring seasoned clinical and commercialization expertise, strengthening oversight for late‑stage development and partner negotiations. Improved board depth supports durable strategic decisions as the company transitions to internally prioritized pipelines.
Bears Say
Negative Cash FlowSustained negative operating and free cash flow means the business is not yet self‑funding; the company depends on its balance sheet and deals to finance operations. Delays in milestones or weaker partner payments would increase financing risk and potential dilution over the medium term.
Large Recurring LossesQuarterly losses of this magnitude relative to modest revenues reflect a structural profitability gap. Continued operating deficits erode equity and constrain returns until clinical assets advance or commercial revenue emerges, making long‑term value dependent on trial success.
Small, Shifting Revenue BaseCurrent revenue is modest and likely to decline as partner‑funded discovery work gives way to internal pipeline investment. That reduces near‑term cash inflows and increases reliance on milestone/royalty outcomes, amplifying revenue volatility until products reach late‑stage development or commercialization.
AbCellera Biologics News
ABCL FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was $2.75 and its highest was $8.44 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is $1.97B.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 16 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on May 11, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.171 by $0.031.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 305,375,400 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.171. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in ABCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.20 (154.36% Upside)
$10.20 (154.36% Upside)
Blogger Sentiment
Neutral
ABCL Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $95.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.76%
12-Months-Change
Fundamentals
Return on Equity
-14.86%
Trailing 12-Months
Asset Growth
-2.76%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
ABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$10.20
▲(154.36% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
40.93% Insiders
4.67% Mutual Funds
0.05% Other Institutional Investors
52.66% Public Companies and Individual Investors